Fig. 6

TCR-T-mediated or Tranilast-mediated cytotoxicity. a Manufactured and expanded TCR-Ts were evaluated for the quantity of cytotoxic CD8+ lymphocytes via cytometry with unstained cells as a negative control and native T cell population as a positive control. b Expanded TCR-Ts were evaluated for the quantity expressing asTCRs via flow cytometry with unstained T cells and native T cells as negative controls. c TCR-T or Tranilast killing effect after co-culturing with ECA109(NY-ESO-1⁻/HLA-A*02:01⁻) ESCC cells; cytotoxicity of various TCR-Ts against ECA109(NY-ESO-1⁻/HLA-A*02:01⁻) at E:T = 1:1 (c(i)), E:T = 2:1 (c(ii)); and the killing effect of Tranilast, selected TCR-T or a combination of both using 120 μM Tranilast or E:T = 1:1 for TCR-Ts and cancer cells (c(iii)). d TCR-T or Tranilast killing effect after co-culturing with ECA109(NY-ESO-1⁺/HLA-A*02:01⁺) ESCC cells; cytotoxicity of various TCR-Ts against ECA109(NY-ESO-1⁺/HLA-A*02:01⁺) at E:T = 1:1 (d(i)), E:T = 2:1 (d(ii)); and the killing effect of Tranilast, selected TCR-T or a combination of both using 120 μM Tranilast or E:T = 2:1 for TCR-Ts and cancer cells (d(iii)). e TCR-T or Tranilast killing effect after co-culturing with OE19(NY-ESO-1⁺/HLA-A*02:01⁺) EADC cells; cytotoxicity of various TCR-Ts against OE19(NY-ESO-1⁺/HLA-A*02:01⁺) at E:T = 1:1 (e(i)), E:T = 2:1 (e(ii)); and the killing effect of Tranilast, selected TCR-T or a combination of both using 120 μM Tranilast or E:T = 2:1 for TCR-Ts and cancer cells (e(iii)). Data are shown as mean ± SD and compared using one-way ANOVA (Brown-Forsythe and Welch tests) with *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001